On the public citation graph
Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database
0 signed · 77 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/14651858.cd006243.pub2openalex-snapshot
Trastuzumab containing regimens for early breast cancer
inferredcites →https://doi.org/10.1002/cncr.33102openalex-snapshot
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
inferredcites →https://doi.org/10.1002/cpt.2055openalex-snapshot
Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration
inferredcites →https://doi.org/10.1002/ijc.34332openalex-snapshot
Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis
inferredcites →https://doi.org/10.1002/pds.1001openalex-snapshot
The reporting odds ratio and its advantages over the proportional reporting ratio
inferredcites →https://doi.org/10.1007/s002280050466openalex-snapshot
A Bayesian neural network method for adverse drug reaction signal generation
inferredcites →https://doi.org/10.1007/s10637-022-01256-0openalex-snapshot
Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis
inferredcites →https://doi.org/10.1007/s40257-021-00645-0openalex-snapshot
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System
inferredcites →https://doi.org/10.1007/s40264-014-0146-yopenalex-snapshot
Performance of Probabilistic Method to Detect Duplicate Individual Case Safety Reports
inferredcites →https://doi.org/10.1007/s40264-021-01091-xopenalex-snapshot
Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020
inferredcites →https://doi.org/10.1007/s40264-022-01210-2openalex-snapshot
Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis
inferredcites →https://doi.org/10.1016/j.clbc.2018.03.005openalex-snapshot
Corneal Changes in Trastuzumab Emtansine Treatment
inferredcites →https://doi.org/10.1016/j.jbc.2021.100826openalex-snapshot
Antibody–receptor interactions mediate antibody-dependent cellular cytotoxicity
inferredcites →https://doi.org/10.1038/s41523-021-00265-1openalex-snapshot
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
inferredcites →https://doi.org/10.1038/sj.clpt.6100258openalex-snapshot
Novel Statistical Tools for Monitoring the Safety of Marketed Drugs
inferredcites →https://doi.org/10.1056/nejm200103153441101openalex-snapshot
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
inferredcites →https://doi.org/10.1056/nejmcibr1909386openalex-snapshot
HER2 and Breast Cancer — A Phenomenal Success Story
inferredcites →https://doi.org/10.1080/14740338.2023.2251380openalex-snapshot
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies
inferredcites →https://doi.org/10.1089/jop.2015.0064openalex-snapshot
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
inferredcites →https://doi.org/10.1097/00003226-200101000-00016openalex-snapshot
Expression of the Receptor Tyrosine Kinases, Epidermal Growth Factor Receptor, ErbB2, and ErbB3, in Human Ocular Surface Epithelia
inferredcites →https://doi.org/10.1097/ico.0000000000000868openalex-snapshot
Abnormal Corneal Lesions Induced by Trastuzumab Emtansine
inferredcites →https://doi.org/10.1158/0008-5472.can-17-3202openalex-snapshot
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
inferredcites →https://doi.org/10.1159/000524176openalex-snapshot
Novel Meibomian Gland and Tarsal Conjunctival Changes Associated with Trastuzumab, Pertuzumab, and Anastrozole Treatment for Metastatic HER2 Positive Breast Cancer: A Case Report and Literature Review
inferredcites →https://doi.org/10.1167/iovs.04-0119openalex-snapshot
Role of ErbB2 in Corneal Epithelial Wound Healing
inferredcites →https://doi.org/10.1186/s12885-015-1969-3openalex-snapshot
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report
inferredcites →https://doi.org/10.1186/s12885-019-5986-5openalex-snapshot
Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
inferredcites →https://doi.org/10.1200/edbk_175630openalex-snapshot
Optimal Management of Early and Advanced HER2 Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2009.23.8451openalex-snapshot
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
inferredcites →https://doi.org/10.1200/jco.2010.29.5865openalex-snapshot
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
inferredcites →https://doi.org/10.1248/bpb.b19-00156openalex-snapshot
Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS
inferredcites →https://doi.org/10.3322/caac.21660openalex-snapshot
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
inferredcites →https://doi.org/10.3389/fimmu.2019.00332openalex-snapshot
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
inferredcites →https://doi.org/10.3389/fonc.2013.00129openalex-snapshot
Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues
inferredcites →https://doi.org/10.3389/fonc.2021.678634openalex-snapshot
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
inferredcites →https://doi.org/10.3390/cancers11060737openalex-snapshot
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
inferredcites →https://doi.org/10.3390/cancers14030512openalex-snapshot
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
inferredcites →https://doi.org/10.3390/cancers15082278openalex-snapshot
Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4852286openalex-extracted
Tumor Necrosis Factor-Alpha Inhibitors-Induced Systemic Lupus Erythematosus: A Real-World Pharmacovigilance Study Based on the Faers Database
inferred← citeshttps://doi.org/10.1007/s00210-025-04428-wopenalex-snapshot
Respiratory, thoracic, and mediastinal adverse events associated with ticagrelor: A pharmacovigilance study based on FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s00403-025-04297-6openalex-snapshot
Disproportionality analyses of Tapinarof-related adverse events based on the FAERS database
inferred← citeshttps://doi.org/10.1007/s00787-025-02694-wopenalex-snapshot
Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database
inferred← citeshttps://doi.org/10.1007/s10549-025-07843-yopenalex-snapshot
Overview of ocular toxicities associated with breast cancer therapies
inferred← citeshttps://doi.org/10.1007/s11095-025-03953-wopenalex-snapshot
Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization
inferred← citeshttps://doi.org/10.1016/j.clbc.2026.10.003openalex-snapshot
2026 Key European Guideline Changes for Metastatic Breast Cancer and Their Impact on Practice—Commentary based on a virtual focus group
inferred← citeshttps://doi.org/10.1016/j.jcjo.2026.06.019openalex-snapshot
Bisphosphonates and glaucoma: a pharmacovigilance signal detection analysis using the FAERS database
inferred← citeshttps://doi.org/10.1038/s41598-025-13502-5openalex-snapshot
A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
inferred← citeshttps://doi.org/10.1038/s41598-025-14064-2openalex-snapshot
Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis
inferred← citeshttps://doi.org/10.1038/s41598-025-90566-3openalex-snapshot
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
inferred← citeshttps://doi.org/10.1080/14740338.2024.2410436openalex-snapshot
A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine
inferred← citeshttps://doi.org/10.1080/14740338.2025.2465872openalex-snapshot
Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database
inferred← citeshttps://doi.org/10.1080/14740338.2025.2466668openalex-snapshot
Comparative safety analysis of Hedgehog inhibitor preparations: insights from the FAERS database
inferred← citeshttps://doi.org/10.1080/14740338.2025.2466673openalex-snapshot
Postmarketing safety of [ 177 Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1080/14740338.2025.2470875openalex-snapshot
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database
inferred← citeshttps://doi.org/10.1080/14740338.2025.2491125openalex-snapshot
Ophthalmotoxicity induced by antibody-drug conjugates: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
inferred← citeshttps://doi.org/10.1080/15569527.2024.2408677openalex-snapshot
Ocular toxicities of FDA-approved antibody drug conjugates
inferred← citeshttps://doi.org/10.1097/md.0000000000049856openalex-snapshot
Assessing the risk of cataracts associated with medications: A pharmacovigilance analysis of the FAERS database
inferred← citeshttps://doi.org/10.1097/md.0000000000050262openalex-snapshot
Safety of ozanimod and etrasimod in ulcerative colitis
inferred← citeshttps://doi.org/10.1111/ceo.70059openalex-snapshot
Ophthalmic Adverse Events of Systemic Immunotherapy and Targeted Cancer Therapy: A Review
inferred← citeshttps://doi.org/10.1136/lupus-2025-001653openalex-snapshot
Characterisation of systemic lupus erythematosus associated with immune checkpoint inhibitors: a pharmacovigilance study using FAERS database
inferred← citeshttps://doi.org/10.1159/000551870openalex-snapshot
Adverse Event Reporting Patterns Associated with Degarelix and Relugolix: A Pharmacovigilance Study Based on the FAERS Database
inferred← citeshttps://doi.org/10.1177/17588359251324889openalex-snapshot
Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer
inferred← citeshttps://doi.org/10.1177/20420986251401122openalex-snapshot
Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1177/20420986251405091openalex-snapshot
Evaluating seizures associated with novel antineoplastic agents during breast cancer treatment using the Food and Drug Administration Adverse Event Reporting System and Canada Vigilance Adverse Reaction Online Database
inferred← citeshttps://doi.org/10.1186/s40360-025-00861-yopenalex-snapshot
The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
inferred← citeshttps://doi.org/10.12659/ajcr.945488openalex-snapshot
Trastuzumab-Induced Early Corneal Melt in HER2-Positive Breast Cancer: A Case Report and Review
inferred← citeshttps://doi.org/10.1371/journal.pone.0331979openalex-snapshot
Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data
inferred← citeshttps://doi.org/10.21203/rs.3.rs-4768570/v1openalex-snapshot
Inflammatory keratitis and trastuzumab in the context of breast cancer - a case report
inferred← citeshttps://doi.org/10.21203/rs.3.rs-7231453/v1openalex-snapshot
Safety Analysis of Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Real-World Study Based on the FAERS Database
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1495137openalex-snapshot
Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1629886openalex-snapshot
Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1698458openalex-snapshot
Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review
inferred← citeshttps://doi.org/10.3389/fmed.2025.1574395openalex-snapshot
Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.3389/fonc.2026.1825180openalex-snapshot
Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study
inferred← citeshttps://doi.org/10.3389/fphar.2024.1425617openalex-snapshot
Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
inferred← citeshttps://doi.org/10.3389/fphar.2024.1458500openalex-snapshot
Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database
inferred← citeshttps://doi.org/10.3389/fphar.2024.1529260openalex-snapshot
Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS
inferred← citeshttps://doi.org/10.3389/fphar.2025.1668446openalex-snapshot
Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.